Source Bioscience Share Discussion Threads

[buywell2] 26/2/2012 10:53

I don´t think it will be long now before we hear of another Trust to adopt FocalPoint

Should prompt a move towards 9p

dyor

[buywell2] 17/2/2012 15:30

However SBS have gone one better and offer HPV testing that can use either SurePath OR ThinPrep


Rapid HPV™ testing

Source BioScience Healthcare are pleased to be able to offer your our brand new Rapid HPV testing service. This unique service eliminates the complexity, stress and expense of in-house HPV testing.

We offer HPV testing using the Abbott RealTime HPV Assay. This is a single test for the detection of 14 HPV High Risk including the genotyping of HPV 16 & HPV 18.

•24 hour turnaround time from receipt of sample
•Reporting via Secure Portal Access (SPA)
•Both SurePath™ and ThinPrep® samples processed•Free daily sample collection
•Approved NHS CSP HPV test
•SurePath™ vial and tube
•CPA accredited laboratory
Cervical cancer is the second most common malignancy in women worldwide. HPV infection is the root cause of developing the disease. There are over 100 different HPV strains with 14 genotypes classified as high risk. HPV 16 and HPV 18 are the most likely genotypes to progress to invasive cancer faster than other High Risk Genotypes.

The Abbott RealTime Assay has been approved by the NHSCSP for Triage of low grade abnormalities and Test of Cure. This assay is reliable and robust with no cross-reactivity with low risk HPV and with a internal control.

For more information or to register for Rapid HPV testing contact us on [e-mail]

[buywell2] 17/2/2012 15:25

It would seem that SurePath , the LBC system that SBS supply to the NHS for cervical cancer screening use , can also be used for HPV testing


High-risk HPV detection in specimens collected in SurePath preservative fluid: comparison of ambient and refrigerated storage.
by A Hardie, C Moore, J Patnick, K Cuschieri, C Graham, ... C Beadling, K Ellis, V Frew, H A Cubie show all authors Medicine › Orthopedics Papers View in Mendeley DesktopIn your librarySave reference to library

official journal of the British Society for Clinical Cytology (2009)
Volume: 20, Issue: 4, Pages: 235-241
PubMed: 19659956
Available from www.ncbi.nlm.nih.gov
or Find this paper at:
openurl.ac.ukWorldCat®Google ScholarEdit library access links Abstract


OBJECTIVE: With moves to introduce human papillomavirus (HPV) triage at sentinel sites in England, it is essential that optimal storage and transport conditions are determined for efficient HPV detection using residual liquid-based cytology specimens. METHODS: Two cytology laboratories with comparable workloads sent residual cervical cytology specimens collected in BD Surepath Preservative Fluid to the Specialist Virology Centre for HPV testing. Storage and transport of specimens was at ambient (site A) or refrigerated (site R) temperatures. The effect of temperature on the ability to detect high-risk human papillomavirus (HR-HPV) using Digene Hybrid Capture 2 High-Risk HPV DNA Test (hc2) and Roche AMPLICOR HPV Test (AMPLICOR) was assessed. All specimens with discordant results were tested using Roche Linear Array HPV Genotyping test. RESULTS: A total of 796 residual cytology specimens, with cytology ranging from normal to severe dyskaryosis, were provided (399 from site A and 397 from site R). Ambient storage and transit of cervical specimens in SurePath medium did not appear to affect significantly the suitability of the specimen for HPV testing, as measured by the concordance of the HR-HPV screening assays for ambient versus refrigerated specimens and by the proportion of specimens which tested invalid. CONCLUSION: Residual cytology specimens in SurePath medium, stored and transported at ambient temperature, appear suitable for HR-HPV detection by AMPLICOR beyond the manufacturer's recommended time and potentially up to four weeks.

[buywell2] 15/2/2012 15:57

New vacancies

Life Science Operations Manager
Based at our Head Quarters in Nottingham and reporting directly to the Chief Operating Officer, this role will have line management responsibility for all the life science services across multiple sites which include Berlin and Dublin. The successful candidate will be expected to strive for continuous improvement in your team, challenge existing practices and lead initiatives to deliver more efficient and effective services for the company and customers. In addition, you will work closely with the Commercial team to ensure our life science products and services are fit for purpose and anticipate future demands, opportunities and constraints.

You are likely to have a science degree perhaps a PhD, previous experience in a similar post, and be knowledgeable and credible in the field of life science research specifically in the area of genomics/molecular biology. You should be familiar with the life science services offered on our website.
Benefits include: private health insurance, life insurance, company pension scheme and subsidised gym membership.

Applicants should send a covering letter and CV with the names and addresses of two referees and your current salary to: Human Resources, Source Bioscience plc, 1 Orchard Place, Nottingham Business Park, Nottingham, NG8 6PX

The closing date for applications is Friday 2nd March 2012.

For more details and a full job specification, please visit: www.sourcebioscience.com/vacancies/

For More Information
Technical and Regional Office Support – Nottingham (Full time 8.00 am to 4.30 pm)
This role requires significant communication with customers, members of the sales and marketing teams internally within the group and Pharma Biotech and externally with suppliers.

Based in our Nottingham office, the post holder will provide technical support on the range of Life Sciences products, clones and services and provide regional office telephone support to our office in Berlin.
The successful candidate must have as a minimum, a science degree or a PhD, be able to demonstrate sufficient skills for the post and be fluent in English and German. Technical LifeSciences experience would also be beneficial

Please apply for the above position by sending a covering letter and a full C.V with the names and addresses of two referees and your current salary to: Human Resources, Source Bioscience plc, 1 Orchard Place, Nottingham Business Park, Nottingham, NG8 6PX

The closing date for applications is Wednesday 1st February 2012 and the Company expects to conduct interviews during the following week.

For More Information
Packaging and Despatch Co-ordinator
This role involves significant internal customer engagement with Customer Services/Commercial the Courier Manager and external worldwide providers.

A co-ordination role with day to day responsibility for the packaging and despatch of products quickly and accurately. The responsibilities include ensuring correct storage of products, back up support for maintaining stock quantities, ordering products from suppliers and sending to the customers. The applicant must have and impressive work ethic, and attention to detail is essential. A scientific background is not necessary but a desire and ability to learn about our products and the storage/transit conditions required is essential.
The successful candidates must have a minimum GCSE or equivalent qualification in English and Maths and be able to demonstrate sufficient skills for the post.

Please apply for the above position by sending a covering letter and a full C.V with the names and addresses of two referees and your current salary to: Human Resources, Source Bioscience plc, 1 Orchard Place, Nottingham Business Park, Nottingham, NG8 6PX

The closing date for applications is Wednesday 1st February 2012 and the Company expects to conduct interviews during the following week.

[hastings] 14/2/2012 17:41

I like your style and your reasoning Buywell, I might have to add!!

[buywell2] 14/2/2012 15:38

The big thing for SBS is to win market share from Hologic for cervical cancer screening provision of LBC consumables.

Remember FocalPoint will only work using Surepath , LBC as supplied to SBS by BD.

Hologic uses ThinPrep

This is worth noting



CONCLUSIONS: Excessive mucus remains a potentially
limiting factor in the ThinPrep Pap system. This appears to be the result of direct obstruction of the filtration membrane causing a markedly diminished retrieval of squamous epithelial cells and potentially impacting disease detection.

The BD SurePath system, conversely, manages mucus by a cell enrichment
process, which results in undiminished cell recovery as observed in this study's test conditions. Cancer (Cancer Cytopathol) 2010;118:244–9. VC 2010 American Cancer Society.

[garbil] 14/2/2012 15:26

With you all the way on that, Buywell.

And as you point out, dividends also help make stocks that much more appealing to fund managers and institutional investors.

(As particularly exemplified - with interest rates so low - by high yielders like BAE
Systems...)

[buywell2] 14/2/2012 15:16

You mentioned AMS

After circa 4 years of profits they have started paying a dividend

Their share price has moved from circa 8p to 80p as a result

At 5m profits SBS would be on a par or better than AMS are now

Whilst AMS have a P/E of circa 24 .... some part of this is due to payment of a dividend

Institutions like this added bonus

If you look at my last post , then SBS at a P/E of 24 would be circa 66p a share in 2015

Without payment of a dividend or a dividend policy stated , then 33p is still my take

[hastings] 14/2/2012 13:08

And i would concur with that view mories. SBS could grow very quickly over the next few years with profits ramping up and no doubt they will look at further complementary acquisitions along with continued expansion. It has three very nice divisions and it could be argued, all are still at a relative early stage in terms of growth potential.

[mories] 14/2/2012 13:01

Whilst I would never turn down a dividend, this is not the type of business that one invests in to get a dividend, it is all about the science and the advancement of the company by investing in new technologies and markets they are developing a great track record and have a super reputation ( i have a relative at uni who is buying sequencing from the company, i ask her if she knew of sourcebio and she was very complimentory having moved the business from glc sp) i would rather they keep investing the profits and the rsult is bigger capital gains for shareholders rather than a few pence in dividends.

[buywell2] 13/2/2012 15:26

Why a dividend statement might soon be coming

The next results could see 17.5m turnover and circa 0.8m profit

Based upon previous posts regarding FocalPoint and HPV turnover growth together with thriving lifesciences increases, 20% turnover growth for the next 4 years could see the following hit

2011 turnover 17.5m .............. profit 0.8m
2012 turnover increase of 20% gives 21m
2013 turnover increase of 20% gives 25.2m
2014 turnover increase of 20% gives 30.04m
2015 turnover increase of 20% gives 36.05m

SBS operates with a margin of circa 40%

The aboves suggests this would equate to 2015 profitable earnings of circa 7.4m at todays prices , minus O/Head and staff cost increases of say 5% a year or 22% over 4 years , gives 7.4 - 1.7 = 5.7m

This would put SBS at 8p on a future 2015 P/E of less than 3

With an undemanding P/E of 12 , which SBS should be trading in 2015 well ahead of ..... this would imply a share price of greater than 4 times that of today or 33p


Now that 0.4m a year is being saved due to buying the freehold of the Nottingham premises , the above looks good

It would seem if 25% of profits were paid out as a dividend policy , then at least 1m would be paid to shareholders in 2015 which would be AFTER the Nottingham premises last payment had been made.

DYOR

[hastings] 13/2/2012 12:46

Heavy volume again and what appears to be a big buy. Somewhat surprised that SBS hasn't delivered a pre-close statement yet, although guess one could come any day.

[mories] 12/2/2012 20:47

As regards Camerons salary, I guess he sees it as his apprenticeship before he moves onto the BIG REWARDS of an ex PM.... I dont hear Tony Blair pleading poverty

[buywell2] 12/2/2012 10:57

............................. NHS REFORMS ...............................

The NHS is the ONLY employer that figures in the top ten employers WORLDWIDE

COLOSSAL: WORLD'S TOP 10 EMPLOYERS

1. U.S. DOD: 3.2 million

2. Chinese Army: 2.3 million

3. Walmart: 2.1 million

4. China Nat.Petrol Corp: 1.7 million

5. State Grid of China: 1.6 million

6. British NHS: 1.4 million

7. Indian Railways: 1.4 million

8. China Post Group: 0.9 million

9. Hon Hai (Taiwan) : 0.8 million



Read more:

Under labour the number of civil servants rose to new highs , the truth of the matter now is that the NHS is too big and costing the country more than it can afford.

Gp´s today are earning circa 130k a year and many are retiring on pensions in excess of 100k a year

It is not suprising that the reforms put more onus on them



That GP´s are now compaining seems to say that 130k a year is not enough

GP's pay will rise by more than 25 per cent and reach £130,000 a year under the government's NHS reforms, according to official figures.

Patients will be appalled to hear that David Cameron plans to pay GPs twice
By Rebecca Smith, Medical Editor
8:30AM GMT 31 Dec 2011

Under a radical shake-up of the NHS, GPs will be responsible for organising health services for their patients.

Figures released under Freedom of Information reveal that GPs will receive up to £115 an hour for commissioning healthcare services, on top of their existing salaries.

The average GP salary last year was £105,700 and in some areas family doctors will be paid a further £26,000 to commission NHS services. Last year 210 GPs earned more than £250,000.



Perhaps they want parity with the Prime Minister

Cameron´s own salary will be reduced to £142,500. He will now be paid less than more than 160 council chiefs.

Cabinet ministers and Deputy PM Nick Clegg will be paid £134,565 - £7,082 less than before - while Ministers of State will pocket £98,740, a cut of £5,197.

[buywell2] 09/2/2012 16:13

Institutional Shareholders


Holder Shares % Held

TD Asset Management, Inc.
as of 01 Oct 2011
20.08m 9.79%
Henderson Global Investors Ltd.
as of 28 Apr 2011
12.85m 9.66%
BlackRock Investment Management (UK) Ltd.
as of 28 Apr 2011
10.12m 4.65%
Barclays Bank Plc (Private Banking)
as of 01 Oct 2011
8.79m 4.22%
Legal & General Investment Management Ltd.
as of 28 Apr 2011
7.00m 3.44%
Swedbank Robur Fonder AB
as of 28 Apr 2011
6.25m 3.07%
Talos Securities Ltd.
as of 01 Oct 2011
6.42m 3.04%
M&G Investment Management Ltd.
as of 01 Oct 2011
4.20m 2.06%
Hargreaves Lansdown Stockbrokers Ltd.
as of 01 Oct 2011
3.51m 2.04%
Hargreave Hale Ltd.
as of 01 Oct 2011
3.08m 1.51%


43.47%
Per cent of shares
held by top holders
Data from 30 Jun 2011 - 01 Feb 2012

[buywell2] 08/2/2012 15:22

The NHS in Wales used FocalPoint for at least two years for Quality Control purposes BEFORE this announcement.

The Data MUST be there to support a roll out of this technology accross the whole of the UK

I wonder how much money Wales have saved in not paying out legal claims to patients as a direct result of FocalPoint useage

Again the data MUST be there



Wales first to adopt new cervical screening technology
Thursday, 22 December 2011
Cervical Screening Wales will become the first screening programme in the UK to adopt new automated technology.

The programme, part of Public Health Wales, will implement the technology across Wales from 1 January 2012 following the publication of National Health Service Cancer Screening Programmes guidelines for its use.

BD FocalPoint technology is produced by the company Source BioScience and is the only automated technology for cervical cancer screening approved for use by the NHS.

It is able to analyse and identify up to 25 per cent of screening samples that can be reported as "all clear", requiring no manual examination.

With more than 200,000 tests undertaken across Wales during 2010/11, this represents a significant reduction in laboratory workload and will also help laboratories achieve the mandatory 14-day screening deadline for results under the Department of Health's Cancer Reform Strategy.

Bryan Rose, Head of Programme for Cervical Screening Wales said: "We are pleased to be the first service to formally adopt the BD FocalPoint system.

"CSW has run an independent assessment of the technology, which has led us to recognise for some time the benefits of using automated imaging for cervical screening.

"The technology will assist our laboratories to improve turnaround times within our defined standards and enhance the quality of service that we provide for women in Wales."

For more information on Cervical Screening Wales, visit:

[hastings] 07/2/2012 21:10

The welsh seemed very keen!

[bobby.ifa] 07/2/2012 17:36

Considering Medicheck want £211 for a testing, this could be a fortune maker, (yes I am a reformed MLS holder of old who has come back into the fold).

[hastings] 07/2/2012 17:25

Indeed Buywell, could be highly significant. Any further news flow over the next few weeks should see the shares edge onwards.

[buywell2] 07/2/2012 15:37

This looks like being a recent development

´´Cervical cancer screening to include HPV testing

HPV testing is to be incorporated into the cervical cancer screening programme from April.



The change was confirmed by the publication of the NHS Cervical Screening Annual Review published on January 7.´´



This I would suggest puts SBS in a very strong position

[buywell2] 07/2/2012 15:37

It has taken a few years for olde stale MLS bulls to leave the fold

Over the last year or so we have seen bigger investors take new or larger stakes as the smaller MLS investors left


The musical chairs could now be over

[mories] 06/2/2012 17:42

I have been adding to my holding following my initial investment after reading shares mag tip, sitting on a nice profit but this is a brilliant company to invest in, it is fully listed so dont have the problems of aim companies and having done a lot more research on the business it has quality from top to bottom in management, the sectors it supplies to are immune to the recession and i can only see growth accross the the board, how on earth has it got this valuation, i can only assume it goes back to the old management who brought it to the brink. great opportunity and all thanks to shares mag.

[buywell2] 06/2/2012 14:49

NHS are running behind on this, but news should be in soon

eGP header
Cervical cancer screening to include HPV testing

HPV testing is to be incorporated into the cervical cancer screening programme from April.



The change was confirmed by the publication of the NHS Cervical Screening Annual Review published on January 7.



HPV testing will mean that screening can be more effectively targeted, reducing unnecessary procedures and the anxiety that they may cause for women.



HPV testing is to be used for women with borderline or low grade cervical abnormalities.



It is intended that it will also lead to greater efficiency and accuracy across the wider NHS Cervical Screening Programme.



Following a successful transfer of cervical screening services, all Cumbria and Lancashire cervical cytology samples are now processed and reported at Central Manchester NHS Foundation Trust in the Manchester Cytology.



Since the transfer of services to Central Manchester, HPV screening has been routinely provided when required on samples from Cumbria and Lancashire.



As a result women in the area benefited from the move in advance of the national guidance published last week.



The Manchester Cytology Centre also implemented Zero Tolerance for discrepancies at sample reception and unscheduled samples ahead of the recommended timescales suggested by North West QARC.



For further information, contact the Pathology Commissioning Team on [e-mail] or the PCT Screening Programme lead.






Cervical Cytology requests and HPV testing

As you will all be aware it is now recognised that high risk Human Papilloma Viruses are responsible for cervical cancer and that the NHS Cervical Screening Programme is moving over to the use of HPV testing as part of the national cervical screening system in the UK. This will take place in two phases and is due to be implemented in Oxfordshire within the next few months. We are currently waiting for the final clearance from national office to proceed with procuring the necessary equipment. As part of this new testing process ALL cervical sample takers are required to undergo further training on the implications of the HPV test results that will be issued in conjunction with the cytology report - the HPV status of the woman will affect how her repeat tests are managed which will naturally cause some distress for patients. This training is being rolled out across Oxfordshire, Berkshire and Buckinghamshire during January to March this year and those sample takers that attend the training session can then cascade train others in the practice.

[buywell2] 06/2/2012 14:33

HPV .... we have not had much news for a while. Looks like the NHS is running courses to teach/roll out what is on offer


NHS Cervical Screening Programme
East Midlands Region

Quality Assurance Reference Centre

A one day course to satisfy NHSCSP mandatory training
requirements for those in Laboratories & Colposcopy Units
Venue: Loughborough
Date: 18th January 2012

Further information is available from our Administration Team
East Pennine Cytology


Human Papillomavirus (HPV)
Testing in the NHS
The Implementation of Human
Papillomavirus (HPV) Triage and
test of Cure

This one day session is designed to conform to NHSCSP Good Practice Guide Number 3* and fulfil
the mandatory requirements of the NHSCSP HPV Triage and Test of Cure Implementation guidance
that all laboratory and colposcopy staff undertake one half day of training. The learning outcomes listed below have been matched to the indicative course content outlined in appendix 6 of that document and the lectures have been designed to cover these learning outcomes.

The day will also be more than suitable for anyone involved in the care pathway from sample takers and those in the screening agencies to those commissioning, planning and managing the implementation of HPV testing into NHS laboratories.

The programme will cover the molecular and epidemiological science of HPV; the protocols that will be used and the results from over three years' experience in Sheffield as one of the Sentinel Sites during the pilot phase. Most importantly it will cover some of the possible and practical difficulties in implementation and the implications for the work of the laboratory as well as
primary care, call / recall and colposcopy. We will also include a number of scenarios to test understanding of the benefits and appropriateness of HPV testing in both the triage and test of cure modality. There will also be a session outlining the next steps for HPV rollout and a question and answer session to help clarify issues arising throughout the day.

The majority of speakers have been involved in the evaluation of implementation of HPV triage and test of cure since it was introduced to Sheffield in January 2008.
Learning Outcomes
At the end of the session individuals should:
• Be aware of the molecular and epidemiological science of HPV
• Understand the rationale behind HPV triage and Test of Cure
• Understand the testing protocols for both test of cure and triage
• Be aware of results from the Sentinel sites project
• Be aware of practical difficulties that might be encountered on rollout
• Be aware of changes to Exeter and other issues around call / recall
• Be aware of the potential use of HPV testing in the management of difficult clinical scenarios
• Be aware of the impact of HPV testing on colposcopy workloads
• Understand the challenges for colposcopy
• Understand the staffing requirements for colposcopy
• Understand the potential impact of HPV testing on cytology reporting and resulting changes to laboratory KC data
• Be aware of the types of cases where HPV triage is most useful
• Be aware of the risks associated with HPV testing
• Have a better understanding of the how HPV rollout will be undertaken
* NHSCSP Guidance – www.csp.nhs.uk/logon.aspx?logout=true

Course Programme
09.15 Coffee & Registration
09.25 Introduction
Implementation of HPV Triage and Test of Cure
Mr Richard French
09.30 Lecture
HPV how does it work and why use it in the screening programme
Mr N Dudding
10.00 Lecture
The Sentinel Site Study protocols for triage and test of cure; Practical guidance on
implementation; the implications for Call / Recall and other pitfalls and problems
Mrs Kay Ellis
11.00 Lecture
Implications for colposcopy and the value of HPV in difficult clinical scenarios
Mr John Tidy
12.00 Question and Answer Session
12.30 Lunch
13.15 Results of the Sentinel Site Study and their impact on laboratory practice
Nr Nick Dudding
14.00 Clinical scenarios around the appropriateness and usefulness of HPV testing
Mr Nick Dudding
14.30 Question and Answer Session
14.45 Towards Rollout - The next steps
Mr Richard French
15.15 Tea / Coffee & Finish
Venue: Holywell Park Conference Centre, The University of Loughborough
Location: The University is situated to the west of Loughborough town centre close to the M1 (junction 23) and the A6. The University is conveniently signposted from either of these main routes. For satellite navigation please use postcode "LE11 3GR" or type "Holywell Way, Loughborough"
Regular rail services operate from London St Pancras, which is a 90 minute journey, then a 10 minute taxi ride from Loughborough station www.nationalrail.co.uk

Parking: There is ample parking available at Holywell Park. Security barriers are in operation at each entrance to the campus. Visitors are asked to report to one of the gatehouses where staff will issue a pass
and direct you to your destination.

Accommodation: Delegate's wishing to extend their stay will find extensive accommodation option at
Burleigh Court or the Link Hotel. Further can details can be found at: www.welcometoimago.com
Cost: This event is free to participants from the East Midlands Region. A £50.00 fee will apply
to delegates outside this region. Lunch and refreshments will be provided. Early registration is
recommended, places will be allocated on a first come first served basis.
Course Faculty
Mr Nick Dudding (FIBMS)
BMS Consultant, Department of Cytology,
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield/ UK.
& Deputy Director East Pennine Cytology Training Centre.
Nick Dudding is a past member of the English Advisory Committee on
Cervical Screening and currently a member of the NHSCSP National Cervical
Cytology Education & Training Committee (NCCETC)
Ms Kay Ellis (FIBMS, DMS, CScI)
BMS Consultant, Cytology
Manager & Hospital-Based Coordinator, Department of Cytology
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield/ UK.
Kay Ellis is a member of both the English Advisory Committee on Cervical
Screening and the NHSCSP HPV Special Interest Group. She was also an
advisor for NHSCSP Good Practice Guide No 3.
Mr John Tidy (MBBS, BSC, MD, FRCOG)
Consultant Gynaecological Oncologist,
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield/ UK.
John Tidy is Secretary of the BSCCP, Chair of the NHSCSP Colposcopy QA
Group and a member of the NHSCSP HPV Special Interest Group
Mr Richard French (CSci, FIBMS)
Deputy Director East Midlands Region Quality Assurance Reference Centre,
Sheffield/UK
Richard French is currently Deputy Director for the East Midlands NHSCSP
and NHSBCSP. He is also a member of the National Evaluation Group for the
Cervical Screening Programme. He entered Quality Assurance from a
background of holding a senior position in a large Cytopathology
department in Leeds.
Further details and an application form are available from the Administration
Team: Tel: [phone] or by email: [e-mail]

[buywell2] 06/2/2012 14:29

Yes

I think 20% increase in turnover for the next 4 years will put SBS on a par